Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Income from Continuing Operations: 2011-2024

Historic Income from Continuing Operations for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $673.7 million.

  • Agios Pharmaceuticals' Income from Continuing Operations fell 110.91% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 160.06%. This contributed to the annual value of $673.7 million for FY2024, which is 291.35% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Income from Continuing Operations is $673.7 million, which was up 291.35% from -$352.1 million recorded in FY2023.
  • Agios Pharmaceuticals' 5-year Income from Continuing Operations high stood at $673.7 million for FY2024, and its period low was -$356.5 million during FY2021.
  • In the last 3 years, Agios Pharmaceuticals' Income from Continuing Operations had a median value of -$231.8 million in 2022 and averaged $29.9 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first tumbled by 51.89% in 2023, then surged by 291.35% in 2024.
  • Agios Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$329.3 million in 2020, then fell by 8.26% to -$356.5 million in 2021, then surged by 34.98% to -$231.8 million in 2022, then tumbled by 51.89% to -$352.1 million in 2023, then surged by 291.35% to $673.7 million in 2024.